FAIR VALUE - Narrative (Details)		3 Months Ended	6 Months Ended
	May 20, 2020 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2020 USD ($)
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Short-term contingent consideration		$ 6,850,000	$ 6,850,000	$ 6,776,000
Long-term contingent consideration		30,809,000	30,809,000	31,776,000
Benefit from change in fair value of contingent consideration		$ 2,200,000	$ 1,600,000
Discounted Cash Flow | Revenue volatility
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input		0.400	0.400
Discounted Cash Flow | Discount rate
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input		0.070	0.070
Discounted Cash Flow | Credit spread
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input		0.052	0.052
Zyla Life Sciences
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration		$ 37,500,000	$ 37,500,000
Short-term contingent consideration		6,900,000	6,900,000
Long-term contingent consideration		30,600,000	30,600,000
CAMBIA
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration		$ 200,000	$ 200,000	$ 200,000
INDOCIN | Zyla Life Sciences | Iroko
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent payment consideration, future royalties covenant, product net sales (over)	$ 20,000,000.0